These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27663824)

  • 1. Drugs in Alzheimer's disease Dementia: An overview of current pharmacological management and future directions.
    Eleti S
    Psychiatr Danub; 2016 Sep; 28(Suppl-1):136-140. PubMed ID: 27663824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.
    Tayeb HO; Yang HD; Price BH; Tarazi FI
    Pharmacol Ther; 2012 Apr; 134(1):8-25. PubMed ID: 22198801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
    Fillit HM; Doody RS; Binaso K; Crooks GM; Ferris SH; Farlow MR; Leifer B; Mills C; Minkoff N; Orland B; Reichman WE; Salloway S
    Am J Geriatr Pharmacother; 2006; 4 Suppl A():S9-S24; quiz S25-S28. PubMed ID: 17157793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia.
    Versijpt J
    J Alzheimers Dis; 2014; 42 Suppl 3():S19-25. PubMed ID: 25061049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease.
    Prvulovic D; Schneider B
    Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):1039-50. PubMed ID: 24785550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethical issues in Alzheimer's disease: an overview.
    Leuzy A; Gauthier S
    Expert Rev Neurother; 2012 May; 12(5):557-67. PubMed ID: 22550984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological treatment of dementia.
    Schwarz S; Froelich L; Burns A
    Curr Opin Psychiatry; 2012 Nov; 25(6):542-50. PubMed ID: 22992546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
    Cacabelos R
    Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current pharmacotherapy for Alzheimer's disease.
    Lleó A; Greenberg SM; Growdon JH
    Annu Rev Med; 2006; 57():513-33. PubMed ID: 16409164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease.
    Prescrire Int; 2003 Dec; 12(68):203-5. PubMed ID: 14986682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Creativity and dementia: emerging diagnostic and treatment methods for Alzheimer's disease.
    Cummings JL; Miller BL; Christensen DD; Cherry D
    CNS Spectr; 2008 Feb; 13(2 Suppl 2):1-20; quiz 22. PubMed ID: 18264030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Therapy of Anti-Tau and Anti-Amyloid Drugs for Disease Modification in Early-stage Alzheimer's Disease: Socio-economic Considerations Modeled on Treatments for Tuberculosis, HIV/AIDS and Breast Cancer.
    Tomaszewski S; Gauthier S; Wimo A; Rosa-Neto P
    J Prev Alzheimers Dis; 2016; 3(3):164-172. PubMed ID: 29205255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and future treatments for Alzheimer's disease.
    Yiannopoulou KG; Papageorgiou SG
    Ther Adv Neurol Disord; 2013 Jan; 6(1):19-33. PubMed ID: 23277790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New and emerging treatments for Alzheimer's disease.
    Corbett A; Smith J; Ballard C
    Expert Rev Neurother; 2012 May; 12(5):535-43. PubMed ID: 22550982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.